bioAffinity Technologies Inc. is a cancer diagnostics company which develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer. bioAffinity Technologies Inc. is based in SAN ANTONIO.
| Revenue (Most Recent Fiscal Year) | $9.36M |
| Net Income (Most Recent Fiscal Year) | $-9.04M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.04 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.79 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -216.86% |
| Net Margin (Trailing 12 Months) | -217.45% |
| Return on Equity (Trailing 12 Months) | -425.87% |
| Return on Assets (Trailing 12 Months) | -162.30% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.65 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.64 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.01 |
| Inventory Turnover (Trailing 12 Months) | 134.32 |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.01 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-20.96 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 4.50M |
| Free Float | 4.35M |
| Market Capitalization | $7.06M |
| Average Volume (Last 20 Days) | 0.11M |
| Beta (Past 60 Months) | 2.41 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.31% |
| Percentage Held By Institutions (Latest 13F Reports) | 1.64% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |